Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study

Clinical Diabetes and Endocrinology
S Ghosal, B Sinha

Abstract

Therapy for Type 2 diabetes (T2D) has been transformed by the introduction of newer agents like Glucagon like Peptide Receptor Agonists (GLP-1RA) and Sodium-glucose linked transporter inhibitors (SGLT2i). However with co-initiation of SGLT2i and GLP-1RA in the DURATION 8 trial an improvement in HbA1c was noted but the beneficial effect was not equal to the sum of its parts. In view of this we proceeded to test the hypothesis that sequential addition of GLP-1RA therapy to metformin and SGLT-2i may be more beneficial. A retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%)on metformin and SGLT2i. All these patients were additionally treated with either Dulaglutide or Liraglutide and followed up for 13 weeks. Across the entire 13-week study period, both liraglutide and dulaglutide proved to be an excellent add on to metformin and SGLT-2 inhibitor. There was significant reduction in HbA1c and body weight. Liraglutide had an additional significant impact on systolic blood pressure reduction in contrast to the dulaglutide arm. Comparatively, liraglutide ...Continue Reading

References

Aug 27, 2015·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Rachel M SarokaRobert A Hamilton
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Sep 22, 2016·The Lancet. Diabetes & Endocrinology·Michael A Nauck, Juris J Meier
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group

❮ Previous
Next ❯

Citations

Jan 12, 2020·Journal of Physiology and Biochemistry·Samuel Álvarez-AlmazánJessica Elena Mendieta-Wejebe
Aug 4, 2018·Current Diabetes Reviews·Mortaza F Hassanabad, Mohammad Fatehi
Jun 12, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Susan RobinsonTessa Kennedy-Martin
Jun 27, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Jee Hee YooWoo Je Lee
Jul 31, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay KalraManilka Sumanatilleke
Dec 11, 2020·Diabetic Medicine : a Journal of the British Diabetic Association·Wasim HanifKamlesh Khunti

❮ Previous
Next ❯

Software Mentioned

SAS ( Statistical Analysis System )
SPSS
Excel
Microsoft Word
SAS
Statistical Package for Social Sciences ( SPSS Complex Samples )

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.